Somatotropinomas, but not nonfunctioning pituitary adenomas, maintain a functional apoptotic RET/Pit1/ARF/p53 pathway that is blocked by excess GDNF

Endocrinology (United States)

Volumn 155, Issue 11, 2014, Pages 4329-4340

  Diaz Rodriguez, Esther ^a   Garcia Rendueles, Angela R ^a   Ibáñez Costa, Alejandro ^c,h   Gutierrez Pascual, Ester ^c   Garcia Lavandeira, Montserrat ^a   Leal, Alfonso ^e   Japon, Miguel A ^e   Soto, Alfonso ^e   Venegas, Eva ^e   Tinahones, Francisco J ^f,h   Garcia Arnes, Juan A ^g   Benito, Pedro ^d,h   Galvez, Maria Angeles ^d   Jimenez Reina, Luis ^c   Bernabeu, Ignacio ^b,h   Dieguez, Carlos ^a,h   Luque, Raul M ^c,h   Castaño, Justo P ^c,h   Alvarez, Clara V ^a,h  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Santiago University Clinical Hospital   (Spain)

^c UNIVERSITY OF CÓRDOBA   (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e UNIVERSITY OF SEVILLE   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^g HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^h Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; ARF PROTEIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH HORMONE; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR RECEPTOR DAX 1; PROTEIN P53; PROTEIN RET; SMALL INTERFERING RNA; STEROIDOGENIC FACTOR 1; TRANSCRIPTION FACTOR PIT 1; POU1F1 PROTEIN, HUMAN; RET PROTEIN, HUMAN;

ACROMEGALY; ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOREGULATION; BINDING SITE; CELL PROLIFERATION; CELLULAR SECRETION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; GROWTH HORMONE SECRETING ADENOMA; GROWTH HORMONE SECRETING CELL; HUMAN; HUMAN CELL; HYPOPHYSIS CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; NONFUNCTIONING PITUITARY ADENOMA; NONHUMAN; PRIMARY CELL CULTURE; PROMOTER REGION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ADENOMA; ANIMAL; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECTS; GENETICS; HYPOPHYSIS TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

ADENOMA; ANIMALS; APOPTOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; PITUITARY NEOPLASMS; PROTO-ONCOGENE PROTEINS C-RET; RATS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR PIT-1; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84908032914     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1034     Document Type: Article

References (53)

1. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119:3189-3202.
2. Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev. 2011;32:247-271.
3. Bernabeu I, Marazuela M, Lucas T, et al. Pegvisomant-induced liver injury is related to the UGT1A1∗28 polymorphism of Gilbert's syndrome. J Clin Endocrinol Metab. 2010;95:2147-2154.
4. van der Lely AJ, Bernabeu I, Cap J, et al. Coadministration of lanreotide autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol. 2011;164:325-333.
5. van der Lely AJ, Biller BM, Brue T, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab. 2012;97:1589-1597.
6. Melmed S, Casanueva FF, Klibanski A, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2013;16:294-302.
7. Urbano AG, Suárez-Peñaranda JM, Diéguez C, Alvarez CV. GDNF and RET-gene expression in anterior pituitary-cell types. Endocrinology. 2000;141:1893-1896.
8. Japón MA, Urbano AG, Sáez C, et al. Glial-derived neurotropic factor and RET gene expression in normal human anterior pituitary cell types and in pituitary tumors. J Clin Endocrinol Metab. 2002;87:1879-1884.
9. Cañibano C, Rodriguez NL, Saez C, et al. The dependence receptor Ret induces apoptosis in somatotrophs through a Pit-1/p53 pathway, preventing tumor growth. EMBO J. 2007;26:2015-2028.
10. Diaz-Rodriguez E, García-Lavandeira M, Perez-Romero S, et al. Direct promoter induction of p19Arf by Pit-1 explains the dependence receptor RET/Pit-1/p53-induced apoptosis in the pituitary somatotroph cells. Oncogene. 2012;31:2824-2835.
11. Komminoth P, Roth J, Muletta-Feurer S, Saremaslani P, Seelentag WK, Heitz PU. RET proto-oncogene point mutations in sporadic neuroendocrine tumors. J Clin Endocrinol Metab. 1996;81:2041-2046.
12. Yoshimoto K, Tanaka C, Moritani M, et al. Infrequent detectable somatic mutations of the RET and glial cell line-derived neurotrophic factor (GDNF) genes in human pituitary adenomas. Endocr J. 1999;46:199-207.
13. Vargiolu M, Fusco D, Kurelac I, et al. The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon receptor-interacting protein to alter survivin availability. J Clin Endocrinol Metab. 2009;94:2571-2578.
14. Heliövaara E, Tuupanen S, Ahlsten M, et al. No evidence of RET germline mutations in familial pituitary adenoma. J Mol Endocrinol. 2010;46:1-8.
15. Luo Y, Tsuchiya KD, Il Park D, et al. RET is a potential tumor suppressor gene in colorectal cancer. Oncogene. 2013;32:2037-2047.
16. Luque RM, Córdoba-Chacón J, Gahete MD, et al. Kisspeptin regulates gonadotroph and somatotroph function in nonhuman primate pituitary via common and distinct signaling mechanisms. Endocrinology. 2011;152:957-966.
17. Garcia-Lavandeira M, Quereda V, Flores I, et al. A GRFa2/Prop1/stem (GPS) cell niche in the pituitary. PLoS One. 2009;4:e4815.
18. Vazquez-Martinez R, Martinez-Fuentes AJ, Pulido MR, et al. Rab18 is reduced in pituitary tumors causing acromegaly and its overexpression reverts growth hormone hypersecretion. J Clin Endocrinol Metab. 2008;93:2269-2276.
19. García A, Alvarez CV, Smith RG, Diéguez C. Regulation of Pit-1 expression by ghrelin and GHRP-6 through the GH secretagogue receptor. Mol Endocrinol. 2001;15:1484-1495.
20. Bordeaux MC, Forcet C, Granger L, et al. The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease. EMBO J. 2000;19:4056-4063.
21. Mulligan LM. RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer. 2014;14:173-186.
22. Solloso A, Barreiro L, Seoane R, et al. GHRHproliferative action on somatotrophs is cell-type specific and dependent on Pit-1/GHF-1 expression. J Cell Physiol. 2008;215:140-150.
23. Garcia-Lavandeira M, Diaz-Rodriguez E, Garcia-Rendueles ME, et al. Functional role of the RET dependence receptor, GFRa co-receptors and ligands in the pituitary. Front Horm Res. 2010;38:127-138.
24. McCormick A, Brady H, Theill LE, Karin M. Regulation of the pituitary-specific homeobox gene GHF1 by cell-autonomous and environmental cues. Nature. 1990;345:829-832.
25. Chen RP, Ingraham HA, Treacy MN, Albert VR, Wilson L, Rosenfeld MG. Autoregulation of pit-1 gene expression mediated by two cis-active promoter elements. Nature. 1990;346:583-586.
26. Ingraham HA, Flynn SE, Voss JW, et al. The POU-specific domain of Pit-1 is essential for sequence-specific, high affinity DNA binding and DNA-dependent Pit-1-Pit-1 interactions. Cell. 1990;61:1021-1033.
27. Asa SL, Bamberger AM, Cao B, Wong M, Parker KL, Ezzat S. The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. J Clin Endocrinol Metab. 1996;81:2165-2170.
28. Aylwin SJ, Welch JP, Davey CL, et al. The relationship between steroidogenic factor 1 and DAX-1 expression and in vitro gonadotropin secretion in human pituitary adenomas. J Clin Endocrinol Metab. 2001;86:2476-2483.
29. Matsuno A, Sasaki T, Mochizuki T, et al. A case of pituitary somatotroph adenoma with concomitant secretion of growth hormone, prolactin, and adrenocorticotropic hormone-an adenoma derived from primordial stem cell, studied by immunohistochemistry, in situ hybridization, and cell culture. Acta Neurochir (Wien). 1996;138:1002-1007.
30. Osamura RY, Egashira N, Kajiya H, et al. Pathology, pathogenesis and therapy of growth hormone (GH)-producing pituitary adenomas: technical advances in histochemistry and their contribution. Acta Histochem Cytochem. 2009;42:95-104.
31. Osamura RY, Tahara S, Komatsubara K, et al. Pit-1 positive α-subunit positive nonfunctioning human pituitary adenomas: a dedifferentiated GH cell lineage? Pituitary. 1999;1:269-271.
32. Wolfe MW, Call GB. Early growth response protein 1 binds to the luteinizing hormone-β promoter and mediates gonadotropin-releasing hormone-stimulated gene expression. Mol Endocrinol. 1999;13:752-763.
33. Fowkes RC, Desclozeaux M, Patel MV, et al. Steroidogenic factor-1 and the gonadotrope-specific element enhance basal and pituitary adenylate cyclase-activating polypeptide-stimulated transcription of the human glycoprotein hormone α-subunit gene in gonadotropes. Mol Endocrinol. 2003;17:2177-2188.
34. Crawford PA, Dorn C, Sadovsky Y, Milbrandt J. Nuclear receptor DAX-1 recruits nuclear receptor corepressor N-CoR to steroidogenic factor 1. Mol Cell Biol. 1998;18:2949-2956.
35. Ingraham HA, Lala DS, Ikeda Y, et al. The nuclear receptor steroidogenic factor 1 acts at multiple levels of the reproductive axis. Genes Dev. 1994;8:2302-2312.
36. Zhao L, Bakke M, Krimkevich Y, et al. Steroidogenic factor 1 (SF1) is essential for pituitary gonadotrope function. Development. 2001;128:147-154.
37. Stallings NR, Hanley NA, Majdic G, Zhao L, Bakke M, Parker KL. Development of a transgenic green fluorescent protein lineage marker for steroidogenic factor 1. Endocr Res. 2002;28:497-504.
38. Hoivik EA, Bjanesoy TE, Mai O, et al. DNAmethylation of intronic enhancers directs tissue-specific expression of steroidogenic factor 1/adrenal 4 binding protein (SF-1/Ad4BP). Endocrinology. 2011;152:2100-2112.
39. Kurelac I, MacKay A, Lambros MB, et al. Somatic complex I disruptive mitochondrial DNA mutations are modifiers of tumorigenesis that correlate with low genomic instability in pituitary adenomas. Hum Mol Genet. 2013;22:226-238.
40. Drouin J. Molecular mechanisms of pituitary differentiation and regulation: implications for hormone deficiencies and hormone resistance syndromes. Front Horm Res. 2006;35:74-87.
41. Shewchuk BM, Asa SL, Cooke NE, Liebhaber SA. Pit-1 binding sites at the somatotrope-specific DNase I hypersensitive sites I, II of the human growth hormone locus control region are essential for in vivo hGH-N gene activation. J Biol Chem. 1999;274:35725-35733.
42. Lin C, Lin SC, Chang CP, Rosenfeld MG. Pit-1-dependent expression of the receptor for growth hormone releasing factor mediates pituitary cell growth. Nature. 1992;360:765-768.
43. Palmieri D, Valentino T, De Martino I, et al. PIT1 upregulation by HMGAproteins has a role in pituitary tumorigenesis. Endocr Relat Cancer. 2012;19:123-135.
44. Koschmieder S, Halmos B, Levantini E, Tenen DG. Dysregulation of the C/EBPα differentiation pathway in human cancer. J Clin Oncol. 2009;27:619-628.
45. Demarco IA, Voss TC, Booker CF, Day RN. Dynamic interactions between Pit-1 and C/EBPα in the pituitary cell nucleus. Mol Cell Biol. 2006;26:8087-8098.
46. Tong Y, Zhou J, Mizutani J, et al. CEBPD suppresses prolactin expression and prolactinoma cell proliferation. Mol Endocrinol. 2011;25:1880-1891.
47. Helftenbein G, Alvarez CV, Tuohimaa P, Beato M. Expression of epithelial phenotype is enhanced by v-Ha-ras in rat endometrial cells immortalized by SV40 T antigen. Oncogene. 1993;8:2075-2085.
48. Califano D, Rizzo C, D'Alessio A, et al. Signaling through Ras is essential for ret oncogene-induced cell differentiation in PC12 cells. J Biol Chem. 2000;275:19297-19305.
49. Gandarillas A. The mysterious human epidermal cell cycle, or an oncogene-induced differentiation checkpoint. Cell Cycle. 2012;11:4507-4516.
50. Musat M, Korbonits M, Kola B, et al. Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr Relat Cancer. 2005;12:423-433.
51. Lin Y, Jiang X, Shen Y, et al. Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocr Relat Cancer. 2009;16:301-310.
52. Murat CB, Braga PB, Fortes MA, Bronstein MD, Corrêa-Giannella ML, Giorgi RR. Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas. Braz J Med Biol Res. 2012;45:851-855.
53. Palumbo T, Faucz FR, Azevedo M, Xekouki P, Iliopoulos D, Stratakis CA. Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN-AKT pathway. Oncogene. 2013;32:1651-1659.